Building awareness of rare diseases is important and relevant for those who are affected and their relatives. Therefore Rare Disease Awareness Day was established by the European Organization for Rare Diseases in 2008 and takes place on the last day of February each year. The aim is to raise awareness and deepen understanding of unknown, overlooked and rare illnesses amongst the general public and decision-makers.

As a European pioneer in the field of rare diseases we contribute to the awareness raising of this important topic. 

Therefore this year we cooperated with the Austrian national newspaper Die Presse dedicating a Round Table discussion to the topic of COVID-19 pandemic impact on the patients with rare disease.

Eva Otter, Vice Secretary of the patient support group PHA Europe, Prof Irene Lang, clinical cardiologist and Professor of Vascular Biology at the Medical University of Vienna, Dr Widmann, Founder, Board Member and Chief Scientific Officer at AOP Orphan, as well as Gerald Bachinger, Patient Advocate shared their valuable experience and perspective on this up-to-date aspect.

The article in German is available in the newspaper Die Presse am Sonntag, from February 28, 2021 and below as download. 

To find out more about rare disease please visit our Rare Disease Story 

For more information, please contact:
AOP Orphan Pharmaceuticals AG
Wilhelminenstraße 91/IIf, 1160 Vienna
Ms. Nina Roth, MAS
T: +43 676 3131509
E: nina.roth@aoporphan.com

AOP Orphan Pharmaceuticals AG is an international pharmaceutical company with its registered office in Vienna and a focus on special diseases with a complex management. Over the past 25 years, the company has become an established provider of holistic therapy solutions from its headquarters in Vienna. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all our stakeholders on the other - especially the patients and their families but also the doctors and care professionals treating them. In the third quarter of 2020, AOP Orphan took over Amomed and SciPharm, two European health care companies, thus continuing its consistent path of growth into a pan-European health care group specializing in special diseases with a complex management.